Deciphex is an American digital pathology application developer, mainly developing digital pathology applications for the clinical research of toxicology pathology. Deciphex introduces artificial intelligence technology into pathology and is committed to developing digital pathology applications. These applications classify high-volume, low-complexity pathology samples, allowing pathologists to focus on analyzing the more difficult and critical pathological image content, improving diagnostic efficiency. Recently, Deciphex raised $11.5 million in Series B financing led by ACT Venture Capital, with participation from Charles River Laboratories, Novartis, IRRUS Investments, Nextsteps Capital, HBAN Medtech Syndicate and other existing investors.
This article is reproduced from: https://www.itjuzi.com/investevent/13234742
This site is for inclusion only, and the copyright belongs to the original author.